Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism

PHASE3CompletedINTERVENTIONAL
Enrollment

151

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Secondary Hypogonadism
Interventions
DRUG

Androxal

oral, capsules, taken one time daily, for 3 months

DRUG

Placebo

Oral capsule taken one time daily for 3 months

Trial Locations (23)

14609

Rochester Clinical Research, Rochester

29464

Coastal Carolina Research Center, Mt. Pleasant

33024

ALL Medical Research, Cooper City

33134

Clinical Research of South Florida, Coral Gables

33143

Well Pharma Medical Research Group, Miami

33169

Phase One Solutions, Miami Gardens

33308

Therafirst Medical Center, Fort Lauderdale

33709

Meridien Research, St. Petersburg

33759

Florida Fertility Institute, Clearwater

33761

Tampa Bay Medical Research, Clearwater

36608

Coastal Clinical Research, Mobile

37920

New Orleans Center for Clinical Research, Knoxville

40509

Central Kentucky Research Associates, Lexington

72205

Baptist Health Center for Clinical Research, Little Rock

84020

Lone Peak Family Medicine, Draper

84120

Granger Medical Clinic, West Valley City

89052

Clinical Research Advantage, Henderson

91356

West Coast Clinical Research, Tarzana

91730

Rancho Cucamonga Clinical Trials, Rancho Cucamonga

92120

San Diego Sexual Medicine, San Diego

92691

Mission Internal Medicine Group, Mission Viejo

92844

SC Clinical Research, Garden Grove

08648

Premier Urology Associates, Lawrenceville

All Listed Sponsors
lead

Repros Therapeutics Inc.

INDUSTRY

NCT01532414 - Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism | Biotech Hunter | Biotech Hunter